Sacituzumab Shows Consistent PFS and OS Benefit in mTNBC

EP: 1.Part 1: Frontline Therapy Options for Rapid Recurrence in Metastatic TNBC

EP: 2.Part 2: Experiences With Sacituzumab and Biomarkers for TNBC

EP: 3.Part 1: Sacituzumab Shows Efficacy in Second-Line Metastatic TNBC

EP: 4.Part 2: Managing Sacituzumab-Associated Neutropenia in TNBC

EP: 5.POLL: What Treatment Would You Choose for BRCA-, PD-L1- Metastatic TNBC?

EP: 6.Part 1: Choosing Therapy for a Patient With Recurrent Metastatic TNBC

EP: 7.Part 2: Managing Toxicities of Sacituzumab Govitecan in Metastatic TNBC

EP: 8.Selecting Frontline Therapy for TNBC After Progression on Adjuvant Therapy

EP: 9.Exploring Sacituzumab Govitecan and Other Second-Line TNBC Therapies

EP: 10.Managing Adverse Events of Sacituzumab Govitecan in TNBC

EP: 11.Managing Sacituzumab AEs and Looking Forward to Next-Line TNBC Therapy

Now Viewing

EP: 12.Sacituzumab Shows Consistent PFS and OS Benefit in mTNBC

EP: 13.Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBC

EP: 14.Sacituzumab Govitecan Shows Efficacy in HR+, HER2- Breast Cancer

EP: 15.Considering the Sequence of ADCs in HR+, HER2- and HER2-Low Breast Cancer

EP: 16.Assessing Factors for Sequencing Therapies in ER+ Advanced Breast Cancer

EP: 17.Adjusting to Practice Changing ADCs in Advanced Breast Cancer

EP: 18.Survival Outcomes with Sacituzumab Govitecan Increase in HR+ mBC

EP: 19.Favorable Toxicity Management with Sacituzumab Govitecan in Advanced Breast Cancer

EP: 20.Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer

EP: 21.UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC

Ruta D. Rao, MD, director, Coleman Foundation Comprehensive Breast Cancer Clinic, medical director of Rush University Cancer Center, and associate professor at Rush Medical College, discussed the trial design and final efficacy results of the ASCENT trial (NCT02574455) of sacituzumab govitecan (Trodelvy) in patients with metastatic triple-negative breast cancer (TNBC).

The phase 3 ASCENT trial enrolled patients who had received at least 2 prior lines of therapy, including a taxane, to receive sacituzumab or a single-agent chemotherapy of physician’s choice, which could be eribulin (Halaven), vinorelbine (Navelbine), capecitabine (Xeloda), or gemcitabine. The primary end point was progression-free survival (PFS).

The results were initially published in 2021, but final data were presented in 2022. This showed a median PFS of 4.8 months for sacituzumab versus 1.7 months for physician’s choice (HR: 0.41; P < .0001), as well as a median overall survival of 11.8 months for sacituzumab versus 6.9 months for patients on physician’s choice chemotherapy (HR: 0.51; P < .0001). These data were consistent with the original publication, which led to the approval of sacituzumab for patients with metastatic TNBC.

TRANSCRIPTION:

0:08 | The ASCENT trial was a randomized phase 3 trial, and these were patients who had metastatic TNBC, and they were [randomly assigned] to receive either sacituzumab or single-agent chemotherapy of physician's choice. And those chemotherapy agents could be eribulin, vinorelbine, capecitabine, or gemcitabine. The primary end point for this trial was PFS. These patients, to be eligible to the trial, had relapsed or refractory metastatic breast cancer that had progressed on 2 or more prior regimens, and they had to have received a taxane either in the early stage or metastatic setting.

1:08 | The trial led [then] to the approval of sacituzumab for TNBC based on meeting its primary end point; it showed an improvement in median PFS. The most recent data showed that the median PFS was 1.7 months for the group of patients who received treatment of physician's choice compared [with] 4.8 months for those who received sacituzumab with a HR of 0.41. [Median] OS was improved by about 5 months from 6.9 [months] to 11.8 months.